What is Olumiant (baricitinib) for?
Buy Olumiant (baricitinib). Olumiant (baricitinib) is used for treating several conditions. It helps patients with:
- Moderate to severe rheumatoid arthritis. This is when other treatments haven’t worked well or caused problems.
- moderate to severe atopic dermatitis in adults. This is for those who need systemic therapy.
On November 19, 2020, the FDA approved Olumiant for COVID-19 treatment. It’s used with Veklury (remdesivir).
EMA is looking into using Olumiant for COVID-19 in patients from 10 years old. These patients need oxygen.
How does Olumiant (baricitinib) work?
Olumiant’s active ingredient, baricitinib, blocks enzymes called Janus kinases. These enzymes are key in inflammation and joint damage in rheumatoid arthritis.
This blocking action reduces inflammation and symptoms of the disease.
Where has Olumiant (baricitinib) been approved?
Olumiant has been approved for treating rheumatoid arthritis in several places. It’s for patients who haven’t responded well to other treatments or can’t tolerate them. It was approved by:
- European Medical Agency (EMA), European Union, February 2, 2017
- Therapeutic Goods Administration (TGA), Australia, January 23, 2018
- Food and Drug Administration (FDA), USA, May 31, 2018.
The FDA also approved Olumiant for COVID-19 treatment on November 19, 2020. Now, it’s used alone for COVID-19 treatment.
EMA is considering extending Olumiant’s use for COVID-19 in patients from 10 years old. These patients need oxygen.
This medicine might be approved in other places too. If you have questions, contact our support team.
How is Olumiant (baricitinib) taken?
The usual dose is:
- 2 to 4mg once a day.
The dose might be lowered to 2mg once a day. This is if the disease is controlled or for certain conditions like kidney function or age.
Warning: Serious infections, like tuberculosis and fungal infections, have happened in patients taking Olumiant.
For more details on dosage and how to take Olumiant, see the official prescribing information. It’s in our references section.
Note: Always talk to your doctor about the right dose for you.
Are there any known side effects or adverse reactions of Olumiant (baricitinib)?
Common adverse reactions
Common side effects include:
- upper respiratory tract infections
- nausea
- herpes simplex
- herpes zoster
- changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids.
Serious adverse reactions
The serious side effects listed include:
- serious infections that can lead to hospitalization or death, such as tuberculosis and other opportunistic infections
- thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis
Use in specific populations
Olumiant (baricitinib) is not recommended for:
- patients with severe liver impairment
- patients with moderate to severe kidney impairment
There is not enough data for its use in pregnant women. It’s best to avoid breastfeeding.